As of close of business last night, Agios Pharmaceuticals Inc’s stock clocked out at $30.29, down -1.66% from its previous closing price of $30.80. In other words, the price has decreased by -$0.51 from its previous closing price. On the day, 518055 shares were traded.
Ratios:
To gain a deeper understanding of AGIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.99 and its Current Ratio is at 12.27. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On February 03, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $41.
Goldman Upgraded its Sell to Neutral on November 17, 2022, whereas the target price for the stock was revised from $17 to $32.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 07 ’24 when Foster-Cheek Kaye I sold 1,285 shares for $31.62 per share. The transaction valued at 40,632 led to the insider holds 5,524 shares of the business.
Foster-Cheek Kaye I sold 4,415 shares of AGIO for $141,236 on Mar 06 ’24. The Director now owns 6,809 shares after completing the transaction at $31.99 per share. On Mar 05 ’24, another insider, Goff Brian, who serves as the Chief Executive Officer of the company, sold 4,156 shares for $32.57 each. As a result, the insider received 135,361 and left with 53,780 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 1.70B and an Enterprise Value of 998.33M. For the stock, the TTM Price-to-Sale (P/S) ratio is 63.46 while its Price-to-Book (P/B) ratio in mrq is 2.09. Its current Enterprise Value per Revenue stands at 37.22 whereas that against EBITDA is -2.59.
Stock Price History:
Over the past 52 weeks, AGIO has reached a high of $35.50, while it has fallen to a 52-week low of $19.80. The 50-Day Moving Average of the stock is 25.99, while the 200-Day Moving Average is calculated to be 25.10.
Shares Statistics:
It appears that AGIO traded 854.92K shares on average per day over the past three months and 785.53k shares per day over the past ten days. A total of 55.95M shares are outstanding, with a floating share count of 54.74M. Insiders hold about 2.58% of the company’s shares, while institutions hold 104.23% stake in the company. Shares short for AGIO as of Feb 29, 2024 were 7.33M with a Short Ratio of 8.58, compared to 7.34M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.05% and a Short% of Float of 13.20%.
Earnings Estimates
As of right now, 9 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.64 for the current quarter, with a high estimate of -$1.48 and a low estimate of -$1.78, while EPS last year was -$1.47. The consensus estimate for the next quarter is -$1.66, with high estimates of -$1.46 and low estimates of -$1.82.
Analysts are recommending an EPS of between -$3.03 and -$7.13 for the fiscal current year, implying an average EPS of -$5.8. EPS for the following year is -$5.87, with 9 analysts recommending between -$3.14 and -$8.8.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $8.8M. It ranges from a high estimate of $12.92M to a low estimate of $7.1M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $5.61M, an estimated increase of 56.90% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $9.61M, an increase of 48.80% less than the figure of $56.90% in the same quarter last year. There is a high estimate of $14.91M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 8 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $62.66M, while the lowest revenue estimate was $31M, resulting in an average revenue estimate of $43.12M. In the same quarter a year ago, actual revenue was $26.82M, up 60.80% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $114.64M in the next fiscal year. The high estimate is $273M and the low estimate is $65.4M. The average revenue growth estimate for next year is up 165.90% from the average revenue estimate for this year.
